Nuvectis Pharma Inc Virtual KOL Event Transcript
Greetings and welcome to the Nuvectis Pharma investor call to discuss the NXP900 Phase 1b program in advanced solid tumors, including the combination with osimertinib in non-small cell lung cancer. (Operator Instructions) Joining me on today's call will be Ron Bentsur, Chairman, Chief Executive Officer, and President of Nuvectis Pharma; Dr. Asier Unciti-Broceta, Professor of Chemistry at the University of Edinburgh; Dr. Alexander Spira, Chief Scientific Officer of Next Oncology. Also joining us for Q&A will be Dr. Enrique Poradosu, Nuvectis' Executive Vice President, Chief Scientific and Business Officer.
Before we begin, I'd like to remind everyone that on this call, we'll be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements within the meaning of the federal securities laws are subject to substantial risks and uncertainties. During this call, all statements other than statements of historical fact are considered forward-looking statements and are based on our interpretations of past events, as well as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
